Browsing by Subject "Chemotherapy"
Now showing items 1-20 of 93
-
Article
Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study
(2003)Background: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied ...
-
Article
Advanced soft-tissue sarcoma and treatment options: Critical appraisal of trabectedin
(2016)Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis ...
-
Article
Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications. A Hellenic co-operative oncology group study
(1998)We have previously shown that metastatic carcinomas of unknown primary site overexpress several tumor markers as well as the products of the oncogenes c-myc, ras and c-erbB2. We analysed the tissue expression of the protein ...
-
Article
Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study
(2004)We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...
-
Article
Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: Pilot study of an effective subtoxic therapy
(2003)Taxane-based chemotherapy has shown activity but also toxicity when administered at standard doses in patients with hormone-resistant prostate cancer (HRPC). In this pilot study, we investigated biweekly low-dose docetaxel ...
-
Article
Cancer and pregnancy: Poena magna, not anymore
(2006)Cancer diagnosed during pregnancy constitutes a difficult clinical condition with a devastating impact on the patient's somatic and psychosocial health and possibly on foetal integrity. This circumstance also raises several ...
-
Article
Caspase-independent pathways of programmed cell death: The unraveling of new targets of cancer therapy?
(2009)In the past few years, accumulating evidence in the literature supports the existence of pathways of caspase-independent programmed cell death (CI-PCD). These pathways are likely to be acting as 'death backup systems' that ...
-
Article
Chemotherapy in clear cell sarcoma
(2011)Clear cell sarcoma is a rare translocation-related sarcoma. There have been few studies documenting the response rate and progression-free survival in clear cell sarcoma patients treated with palliative chemotherapy. The ...
-
Article
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support
(2000)Several cancer therapeutic agents have been associated with pulmonary toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema ...
-
Article
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study
(1994)The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally ...
-
Article
Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study
(1997)From June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) ...
-
Article
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma
(1994)From June 1985 to March 1993, 20 consecutive patients with histologically proven malignant mesothelioma were treated with cisplatin 100 mg/m2 i.v. infusion on day 1 and vinblastine 6 mg/m2 i.v. on day 1 and 8. Treatment ...
-
Article
Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer
(1999)Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...
-
Article
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study
(1998)The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...
-
Article
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis
(2009)Objectives: To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). Data sources: PubMed and the Cochrane Library Central ...
-
Article
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients
(1996)362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...
-
Conference Object
Deriving quantitative structure-activity relationship models using genetic programming for drug discovery
(2008)Genetic Programming is a heuristic search algorithm inspired by evolutionary techniques that has been shown to produce satisfactory solutions to problems related to several scientific domains [1]. Presented here is a ...
-
Conference Object
Design rules for cancer nanomedicines
(Affiliation: Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, CyprusAffiliation: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesCorrespondence Address: Stylianopoulos, T.Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus, 2012)The use of nanotechnology has offered new hope for cancer detection, prevention and treatment. Nanoparticle formulations are advantageous over conventional chemotherapy because they can incorporate multiple diagnostic and ...
-
Article
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
(2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...
-
Article
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
(2001)Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. ...